Published Year: 2023
Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis: Focus on Product Typ
The global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022...
Market Research Report
A quick peek into the report
Table of Contents
1.1 Inclusion and Exclusion
2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Selection Criteria for Company Profiles
3.1 Introduction
3.2 Cell and Gene Therapy and Their Clinical Importance
3.3 Cell and Gene Therapy Development and Commercialization Landscape
3.4 Global Cell and Gene Therapy Market Size, 2020-2027
3.5 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy
3.6 Reimbursement and Market Access
3.6.1 Reimbursement Scenario of Cell and Gene Therapy Market, by Country
3.6.1.1 U.S.
3.6.1.2 EU 5
3.6.1.2.1 France
3.6.1.2.2 Germany
3.6.1.2.3 Italy
3.6.1.2.4 Spain
3.6.1.2.5 U.K.
3.7 Key Companies in Cell and Gene Therapy Market and their Contributions
4.1 Cell and Gene Therapy Industry
4.2 Key Successful Cell and Gene Therapy Commercialization
4.2.1 Regional Addressable Market and Growth Potential
4.3 North America
4.4 Europe
4.5 Asia-Pacific
4.6 Latin America
4.7 Rest-of-the-World
5.1 Disruption of Cell and Gene Therapy Market Due to COVID-19
5.2 COVID-19 Affecting Supply Chain of Cell and Gene Therapy Market
5.3 Interruption in Research and Clinical Development and Commercial Operation
5.3.1 Research and Clinical Development
5.3.2 Commercial Operation and Access
5.4 Navigating Crisis Recovery and Looking to the Future
6.1 Legal and Regulatory Framework and Requirements
6.1.1 Overview of Regulatory Pathway for Cell and Gene Therapy
6.1.1.1 Fast Track Designation:
6.1.1.2 Breakthrough Therapy:
6.1.1.3 Accelerated Approval:
6.1.1.4 Priority Review:
6.1.1.5 Regenerative Medicine Advanced Therapy Designation:
6.1.2 Expedited Designation Vs. Traditional Approval Timelines:
6.1.3 Regulatory Challenges
6.1.4 Successful Regulatory Strategies
Patent Landscape
8.1 Viral Vector Manufacturing
8.1.1 Retrovirus
8.1.2 Lentivirus
8.1.3 AAV
8.1.4 Adenovirus
8.2 Upstream Manufacturing
8.2.1 Cost Consideration and Timelines
8.2.2 Process Design and Regulatory Burdens
8.2.3 Other Considerations
8.3 Downstream Manufacturing
8.3.1 Cost Considerations and Timelines
8.3.2 Challenges in Downstream
8.3.3 Scale-Up of Downstream from Research to Clinical Manufacturing
8.4 Non-Viral Vector Manufacturing
8.4.1 Non-Viral, Plasmid-Free Manufacturing
8.4.2 Plasmid
8.4.3 Naked DNA
8.4.4 Physical-Mediated Methods
8.5 Cell and Gene Therapy Manufacturing Capacity, by Company
9.1 Overview
9.2 Market Drivers
9.2.1 Increasing Incidences of Cancer and Other Chronic Diseases
9.2.2 High Number of Rare Diseases Across Globe
9.2.3 Rising Number of Clinical Trials
9.2.4 Increasing Funding and Investments in Cell and Gene Therapy Market
9.2.5 Favorable Regulatory Environment for Cell and Gene Therapy Products
9.3 Market Restrains
9.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy
9.3.2 Complex Manufacturing and Distribution Setup
9.3.3 Tedious Process of Therapeutic Commercialization
9.4 Market Opportunities
9.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies
9.4.2 Increasing Number of Mergers and Acquisitions within the Cell and Gene Industry
10.1 Key Strategies and Development
10.1.1 Product Offerings and Approvals
10.2 Synergistic Activities
10.3 Funding and Business Expansions
10.4 Mergers and Acquisitions
10.5 Market Share Analysis
10.6 Growth-Share Analysis (by Company), 2020
11.1 Therapeutic Market
11.1.1 Yescarta
11.1.2 Provenge
11.1.3 Luxturna
11.1.4 Kymriah
11.1.5 Imlygic
11.1.6 Gintuit
11.1.7 MACI
11.1.8 Gendicine
11.1.9 Oncorine
11.1.10 Neovasculgen
11.1.11 Strimvelis
11.1.12 Invossa
11.1.13 Zolgensma
11.1.14 Tecartus
11.1.15 Liso-Cel
11.1.16 Zyntelego
11.1.17 Others
11.2 Pipeline Analysis
11.2.1 Phase 1
11.2.2 Phase 2
11.2.3 Phase 3
11.2.3.1 SPK-8011
11.2.3.2 OTL-103
11.2.3.3 OTL-200
11.2.3.4 OTL-101
11.2.3.5 VM202
11.2.3.6 GS010
11.2.3.7 bb2121
11.2.3.8 PTC-AADC
11.2.4 Pipeline Analysis – CAR-T Focused
11.2.5 Pipeline Analysis – CAR-NK Focused
12.1 Overview
12.2 Rare Diseases
12.3 Oncology
12.4 Hematology
12.5 Cardiovascular
12.6 Ophthalmology
12.7 Neurology
12.8 Other Therapeutic Classes
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.1.1 Approved Products
13.2.1.2 Competitive Landscape
13.2.1.3 Market Size and Forecast
13.2.1.4 Key Developments
13.2.2 Canada
13.2.2.1 Approved Products
13.2.2.2 Market Size and Forecast
13.2.2.3 Key Developments
13.3 Europe
13.3.1 Europe Cell and Gene Therapy Market Dynamics
13.3.2 Germany
13.3.2.1 Approved Products
13.3.2.2 Market Size and Forecast
13.3.2.3 Key Developments
13.3.3 France
13.3.3.1 Approved Products
13.3.3.2 Market Size and Forecast
13.3.3.3 Key Developments
13.3.3.4 Competitive Landscape
13.3.4 U.K.
13.3.4.1 Approved Products
13.3.4.2 Market Size and Forecast
13.3.4.3 Competitive Landscape
13.3.5 Italy
13.3.5.1 Approved Products
13.3.5.2 Market Size and Forecast
13.3.5.3 Key Developments
13.3.6 Spain
13.3.6.1 Approved Products
13.3.6.2 Market Size and Forecast
13.3.6.3 Key Developments
13.3.6.4 Competitive Landscape
13.3.7 The Netherlands
13.3.7.1 Approved Products
13.3.7.2 Market Size and Forecast
13.3.7.3 Key Developments
13.3.7.4 Competitive Landscape
13.3.8 Russia
13.3.8.1 Approved Products
13.3.8.2 Market Size and Forecast
13.3.8.3 Competitive Landscape
13.3.9 Rest-of-Europe
13.3.9.1 Market Size and Forecast
13.3.9.2 Key Developments
13.4 Asia-Pacific (APAC)
13.4.1 Japan
13.4.1.1 Approved Products
13.4.1.2 Market Size and Forecast
13.4.1.3 Key Developments
13.4.1.4 Competitive Landscape
13.4.2 China
13.4.2.1 Approved Products
13.4.2.2 Market Size and Forecast
13.4.2.3 Key Developments
13.4.2.4 Competitive Landscape
13.4.3 Australia
13.4.3.1 Approved Products
13.4.3.2 Market Size and Forecast
13.4.3.3 Key Developments
13.4.4 South Korea
13.4.4.1 Approved Products
13.4.4.2 Market Size and Forecast
13.4.4.3 Key Developments
13.4.4.4 Competitive Landscape
13.4.5 India
13.4.5.1 Approved Products
13.4.5.2 Market Size and Forecast
13.4.5.3 Competitive Landscape
13.4.6 Singapore
13.4.6.1 Approved Products
13.4.6.2 Market Size and Forecast
13.4.6.3 Key Developments
13.4.7 Rest-of-Asia-Pacific
13.4.7.1 Market Size and Forecast
13.4.7.2 Key Developments
13.5 Latin America
13.5.1 Brazil
13.5.1.1 Market Size and Forecast
13.5.2 Mexico
13.5.2.1 Market Size and Forecast
13.5.3 Rest-of-Latin America (RoLA)
13.5.3.1 Market Size and Forecast
13.6 Rest-of-World
13.6.1 Market Size and Forecast
14.1 Amgen Inc.
14.1.1 Company Overview
14.1.2 Role of Amgen Inc. in the Global Cell and Gene Therapy Market
14.1.3 Financials
14.1.4 Key Insights About Financial Health of the Company
14.1.5 SWOT Analysis
14.2 bluebird bio, Inc.
14.2.1 Company Overview
14.2.2 Role of bluebird bio, Inc. in the Global Cell and Gene Therapy Market
14.2.3 Financials
14.2.4 Key Insights About Financial Health of the Company
14.2.5 SWOT Analysis
14.3 Dendreon Pharmaceuticals LLC.
14.3.1 Company Overview
14.3.2 Role of Dendreon Pharmaceuticals LLC. in the Global Cell and Gene Therapy Market
14.3.3 SWOT Analysis
14.4 Castle Creek Pharmaceutical Holdings
14.4.1 Company Overview
14.4.2 Role of Castle Creek Pharmaceutical Holdings in the Global Cell and Gene Therapy Market
14.4.3 SWOT Analysis
14.5 Human Stem Cells Institute
14.5.1 Company Overview
14.5.2 Role of Human Stem Global Cell and Gene Therapy Cell Market
14.5.3 SWOT Analysis
14.6 Kite Pharma, Inc.
14.6.1 Company Overview
14.6.2 Role of Kite Pharma, Inc. in the Global Cell and Gene Therapy Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 Kolon TissueGene, Inc.
14.7.1 Company Overview
14.7.2 Role of Kolon TissueGene, Inc. in the Global Cell and Gene Therapy Market
14.7.3 SWOT Analysis
14.8 Novartis AG
14.8.1 Company Overview
14.8.2 Role of Novartis AG in the Global Cell and Gene Therapy Market
14.8.3 Financials
14.8.4 Key Insights About Financial Health of the Company
14.8.5 SWOT Analysis
14.9 Orchard Therapeutics plc.
14.9.1 Company Overview
14.9.2 Role of Orchard Therapeutics plc. in the Global Cell and Gene Therapy Market
14.9.3 Financials
14.9.4 SWOT Analysis
14.10 Organogenesis Holdings Inc.
14.10.1 Company Overview
14.10.2 Role of Organogenesis Holdings Inc. in the Global Cell and Gene Therapy Market
14.10.3 Financials
14.10.4 Key Insights About Financial Health of the Company
14.10.5 SWOT Analysis
14.11 Pfizer, Inc.
14.11.1 Company Overview
14.11.2 Role of Pfizer, Inc. in the Global Cell and Gene Therapy Market
14.11.3 Financials
14.11.4 Key Insights About Financial Health of the Company
14.11.5 SWOT Analysis
14.12 RENOVA THERAPEUTICS
14.12.1 Company Overview
14.12.2 Role of RENOVA THERAPEUTICS in the Global Cell and Gene Therapy Market
14.12.3 SWOT Analysis
14.13 Shanghai Sunway Biotech Co., Ltd.,
14.13.1 Company Overview
14.13.2 Role of Shanghai Sunway Biotech Co., Ltd., in the Global Cell and Gene Therapy Market
14.13.3 SWOT Analysis
14.14 Sibiono GeneTech Co. Ltd.,
14.14.1 Company Overview
14.14.2 Role of Sibiono GeneTech Co. Ltd., in the Global Cell and Gene Therapy
14.14.3 SWOT Analysis
14.15 Spark Therapeutics, Inc.
14.15.1 Company Overview
14.15.2 Role of Spark Therapeutics, Inc. in the Global Cell and Gene Test Market
14.15.3 Financials
14.15.4 Key Insights About Financial Health of the Company
14.15.5 SWOT Analysis
14.16 Vericel Corporation
14.16.1 Company Overview
14.16.2 Role of Vericel Corporation in the Global Cell and Gene Therapy Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
Table 3.1: Approved Gene Therapies Worldwide
Table 3.2: Key Companies in Cell and Gene Therapy Market, 2020
Table 4.1: Key Products of Cell and Gene Therapy Market
Table 8.1: Key Viral Vectors
Table 8.2: Cell and Gene Therapy Manufacturing Capacity (by Company)
Table 9.1: Number of Clinical Trials for Cell and Gene Therapy, 2020
Table 11.1: List of key Cell/Gene Therapy Products with Marketing Authorization (MA)
Table 11.2: Key Cell and Gene Therapy Drugs in Phase 3, 2020
Table 12.1: List of Cell and Gene Therapy Products with Marketing Authorization in the European Union by EMA
Figure 1: Cell and Gene Therapy Funding (2019 and 2020-H1)
Figure 2: Global Cell and Gene Therapy Market, 2020-2027
Figure 3: Market Drivers, Opportunities, and Restraints
Figure 4: Share of Key Developments and Strategies, January 2016-January 2021
Figure 5: Global Cell and Gene Therapy Market Share (Product Type), 2020-2027
Figure 6: Global Cell and Gene Therapy Market Share (by Therapeutic Class), 2020-2027
Figure 7: Global Cell and Gene Therapy Market (by Region)
Figure 1.1: Definitions of Cell and Gene Therapies
Figure 2.1: Global Cell and Gene Therapy Market Research Methodology
Figure 2.2: Primary Research Methodology
Figure 2.3: Global Cell and Gene Therapy Market Research Methodology Approach
Figure 2.4: Total Number of Companies Profiled
Figure 3.1: Clinical Trials by Therapeutic Category, Regenerative Medicines and Advanced Therapies, 2020
Figure 3.2: Global Cell and Gene Therapy Market Size, 2020-2027
Figure 3.3: Factors Involved in Payer Decision Flow, Process Considerations and Stakeholder Drivers in Reimbursement in U.S.
Figure 3.4: Emerging Payment Models for Cell and Gene Therapies in Europe
Figure 4.1: Addressable Market Size of Commercialized Products, 2020
Figure 4.2: Global Cell and Gene Therapy Market, 2020-2027
Figure 4.3: North America Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.4: Europe Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.5: Asia-Pacific Cell and Gene Therapy Addressable Market, 2020 Vs 2027
Figure 4.6: Latin America Cell and Gene Therapy Addressable Market 2020 Vs 2027
Figure 5.1: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020, to April 12, 2020)
Figure 5.2: Pre-COVID-19 and Post-COVID-19 Scenario of Global Cell and Gene Therapy Market, 2020-2025
Figure 5.3: Areas of Disruption in Clinical Development
Figure 5.4: Measure to Navigate Crisis Recovery
Figure 6.1: Expedited Approval Designations for Cell and Gene Therapies
Figure 7.1: Number of Patents (by Year), 2016-2020
Figure 7.2: Share of Patents (by Country), 2016-2021
Figure 8.1: Steps Involved in Bioprocessing
Figure 8.2: Typical Production Methods of Viral Vectors
Figure 8.3: Typical Production Method of Plasmid Vectors
Figure 9.1: Impact Analysis of Market Dynamics
Figure 9.2: Rising Incidences of Cancer (2015 and 2018)
Figure 9.3: Prevalence of Rare Diseases
Figure 9.4: Deal Value of Mergers and Acquisitions (2016-2019)
Figure 10.1: Share of Key Developments and Strategies, January 2016- January 2021
Figure 10.2: Share of Product Offerings and Approvals, January 2016-January 2021
Figure 10.3: Share of Synergistic Activities, January 2016-January 2021
Figure 10.4: Share of Funding and Expansions, January 2016-January 2021
Figure 10.5: Share of Mergers and Acquisitions, January 2016-January 2021
Figure 10.6: Market Share Analysis: Global Cell and Gene Therapy Market, 2020
Figure 10.7: Growth-Share Matrix for Global Cell and Gene Therapy Market (by Company), 2020
Figure 11.1: Global Cell and Gene Therapy Market (by Therapeutic Drugs), 2020-2027
Figure 11.2: Global Revenue for Yescarta, 2020-2027
Figure 11.3: Global Revenue for Provenge, 2020-2027
Figure 11.4: Global Revenue for Luxturna, 2020-2027
Figure 11.5: Global Revenue for Kymriah, 2020-2027
Figure 11.6: Global Revenue for Imlygic, 2020-2027
Figure 11.7: Global Revenue for MACI, 2020-2027
Figure 11.8: Global Revenue for Gendicine, 2020-2027
Figure 11.9: Global Revenue for Oncorine, 2020-2027
Figure 11.10: Global Revenue for Neovasculogen, 2020-2027
Figure 11.11: Global Revenue for Strimvelis, 2020-2027
Figure 11.12: Global Revenue for Invossa, 2020-2027
Figure 11.13: Global Revenue for Zolgensma, 2020-2027
Figure 11.14: Global Revenue for Tecartus, 2020-2027
Figure 11.15: Global Revenue for Other Drugs, 2020-2027
Figure 11.16: Global Revenue for Other Drugs, 2020-2027
Figure 11.17: Global Revenue for Other Drugs, 2020-2027
Figure 11.18: Cell and Gene Therapy Medicines in Development by Disease, 2018
Figure 11.19: Number of Phase 1 Clinical Trials for Cell and Gene Therapy, 2018-2020
Figure 11.20: Number of Phase 2 Clinical Trials for Cell and Gene Therapy, 2018-2020
Figure 11.21: Global Cell and Gene Therapy Market, by Late Phase, 2021-2027
Figure 11.22: Global Revenue for SPK-8011, 2020-2027
Figure 11.23: Global Revenue for OTL-103, 2021-2027
Figure 11.24: Global Revenue for OTL-200, 2020-2027
Figure 11.25: Global Revenue for OTL-101, 2021-2027
Figure 11.26: Global Revenue for VM 202, 2021-2027
Figure 11.27: Global Revenue for GS010, 2021-2027
Figure 11.28: Global Revenue for bb2121, 2021-2027
Figure 11.29: Global Revenue for PTC-AADC, 2021-2027
Figure 11.30: Pipeline For CAR-T Therapies (2020)
Figure 12.1: Global Cell and Gene Therapy Market (Rare Diseases), 2020-2027
Figure 12.2: Global Cell and Gene Therapy Market (Oncology), 2020-2027
Figure 12.3: Global Cell and Gene Therapy Market (Hematology), 2020-2027
Figure 12.4: Global Cell and Gene Therapy Market (Cardiovascular Disease), 2020-2027
Figure 12.5: Global Cell and Gene Therapy Market (Ophthalmology), 2020-2027
Figure 12.6: Global Cell and Gene Therapy Market (Neurology), 2020-2027
Figure 12.7: Global Cell and Gene Therapy Market (Other Therapeutic Class), 2020-2027
Figure 12.8: Global Cell and Gene Therapy Market (by Region)
Figure 12.9: North America Global Cell and Gene Therapy Market, 2020-2027
Figure 12.10: North America: Market Dynamics
Figure 12.11: U.S. Cell and Gene Therapy Market, 2020-2027
Figure 12.12: Canada Cell and Gene Therapy Market, 2020-2027
Figure 12.13: Europe Cell and Gene Therapy Market, 2020-2027
Figure 12.14: Europe: Market Dynamics
Figure 12.15: Germany Cell and Gene Therapy Market, 2020-2027
Figure 12.16: France Cell and Gene Therapy Market, 2020-2027
Figure 12.17: U.K. Cell and Gene Therapy Market, 2020-2027
Figure 12.18: Italy Cell and Gene Therapy Market, 2020-2027
Figure 12.19: Spain Cell and Gene Therapy Market, 2020-2027
Figure 12.20 Netherlands Cell and Gene Therapy Market, 2020-2027
Figure 12.21: Russia Cell and Gene Therapy Market, 2020-2027
Figure 12.22: Rest-of-Europe Cell and Gene Therapy Market, 2020-2027
Figure 12.23: Asia-Pacific Cell and Gene Therapy Market, 2020-2027
Figure 12.24: Asia-Pacific Market Dynamics
Figure 12.25: Japan Cell and Gene Therapy Market, 2020-2027
Figure 12.26: China Cell and Gene Therapy Market, 2020-2027
Figure 12.27: Australia Cell and Gene Therapy Market, 2020-2027
Figure 12.28: South Korea Cell and Gene Therapy Market, 2020-2027
Figure 12.29: India Cell and Gene Therapy Market, 2020-2027
Figure 12.30: Singapore Cell and Gene Therapy Market, 2020-2027
Figure 12.31: Rest-of-Asia-Pacific Cell and Gene Therapy Market, 2020-2027
Figure 12.32: Latin America Cell and Gene Therapy Market, 2020-2027
Figure 12.33: Latin America: Market Dynamics
Figure 12.34: Brazil Cell and Gene Therapy Market, 2020-2027
Figure 12.35: Mexico Cell and Gene Therapy Market, 2020-2027
Figure 12.36: Rest-of-Latin America Cell and Gene Therapy Market, 2020-2027
Figure 12.37: Rest-of-World Cell and Gene Therapy Market, 2020-2027
Figure 13.1: Amgen Inc.: Overall Product Portfolio
Figure 13.2: Amgen Inc.: Pipeline Product Portfolio
Figure 13.3: Amgen Inc.: Overall Financials, 2017-2019
Figure 13.4: Amgen Inc.: Revenue (by Region), 2017-2019
Figure 13.5: Amgen Inc.: R&D Expenditure, 2017-2019
Figure 13.6: Amgen Inc.: SWOT Analysis
Figure 13.7: Pipeline Product Portfolio: bluebird bio, Inc.
Figure 13.8: bluebird bio, Inc.: Overall Financials, 2017-2019
Figure 13.9: bluebird bio, Inc.: R&D Expenditure, 2017-2019
Figure 13.10: bluebird bio, Inc.: SWOT Analysis
Figure 13.11: Dendreon Pharmaceuticals LLC: Product Portfolio
Figure 13.12: Dendreon Pharmaceuticals LLC.: SWOT Analysis
Figure 13.13: Castle Creek Pharmaceutical Holdings: Overall Product Portfolio
Figure 13.14: Castle Creek Pharmaceutical Holdings : Pipeline Product Portfolio
Figure 13.15: Castle Creek Pharmaceutical: SWOT Analysis
Figure 13.16: Human Stem Cell Institute: Overall Product Portfolio
Figure 13.17: Human Stem Cell Institute: SWOT Analysis
Figure 13.18: Kite Pharma, Inc.: Overall Product Portfolio
Figure 13.19: Kite Pharma, Inc.: Pipeline Product Portfolio
Figure 13.20: Kite Pharma, Inc.: Overall Financials, 2016-2018
Figure 13.21: Kite Pharma, Inc.: R&D Expenditure, 2016-2018
Figure 13.22: Kite Pharma, Inc.: SWOT Analysis
Figure 13.23: Kolon TissueGene, Inc.: Pipeline Product Portfolio
Figure 13.24: Kolon TissueGene, Inc.: SWOT Analysis
Figure 13.25: Novartis AG: Overall Product Portfolio
Figure 13.26: Novartis AG: Pipeline Product Portfolio
Figure 13.27: Novartis AG: Overall Financials, 2017-2019
Figure 13.28: Novartis AG: Revenue (by Business Segment), 2017-2019
Figure 13.29: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 13.30: Novartis AG: R& D Expense, 2017-2019
Figure 13.31: Novartis AG: SWOT Analysis
Figure 13.32: Orchard Therapeutics plc.: Pipeline Product Portfolio
Figure 13.33: Orchard Therapeutics plc.: Overall Financials, 2017-2019
Figure 13.34: Orchard Therapeutics plc: SWOT Analysis
Figure 13.35: Organogenesis Holdings Inc.: Overall Product Portfolio
Figure 13.36: Organogenesis Holdings Inc.: Overall Financials, 2017-2019
Figure 13.37: Organogenesis Holdings Inc.: R&D Expenditure, 2017-2019
Figure 13.38: Organogenesis Holdings Inc.: SWOT Analysis
Figure 13.39: Pfizer, Inc.: Overall Product Portfolio
Figure 13.40: Pfizer, Inc.: Pipeline Product Portfolio
Figure 13.41: Pfizer, Inc.: Overall Financials, 2017-2019
Figure 13.42: Pfizer, Inc.: Revenue (by Region), 2017-2019
Figure 13.43: Pfizer, Inc.: R&D Expenditure, 2017-2019
Figure 13.44: Pfizer, Inc.: SWOT Analysis
Figure 13.45: RENOVA THERAPEUTICS: Pipeline Product Portfolio
Figure 13.46: RENOVA THERAPEUTICS: SWOT Analysis
Figure 13.47: Product Portfolio: Shanghai Sunway Biotech Co., Ltd.,
Figure 13.48: Shanghai Sunway Biotech Co., Ltd.: SWOT Analysis
Figure 13.49: Sibiono GeneTech Co. Ltd.: Overall Product Portfolio
Figure 13.50: Sibiono GeneTech Co. Ltd.: SWOT Analysis
Figure 13.51: Spark Therapeutics, Inc.: Overall Product Portfolio
Figure 13.52: Spark Therapeutics, Inc.: Pipeline Product Portfolio
Figure 13.53: Spark Therapeutics, Inc.: Overall Financials, 2017-2019
Figure 13.54: Spark Therapeutics, Inc.: R&D Expenditure, 2017-2019
Figure 13.55: Spark Therapeutics, Inc.: SWOT Analysis
Figure 13.56: Vericel Corporation: Overall Product Portfolio
Figure 13.57: Vericel Corporation: Overall Financials, 2017-2019
Figure 13.58: Vericel Corporation: Revenue (by Product), 2017-2019
Figure 13.59: Vericel Corporation: R&D Expenditure (2017-2019)
Figure 13.60: Vericel Corporation: SWOT Analysis
Report Description
|
Market Report Coverage - Cell and Gene Therapy |
|||
|
Base Year |
2020 |
Market Size in 2020 |
$2,599.7 Million |
|
Forecast Period |
2021-2027 |
Value Projection and Estimation by 2027 |
$25,002.1 Million |
|
CAGR During Forecast Period |
33.82% |
Number of Tables |
9 |
|
Number of Pages |
285 |
Number of Figures |
170 |
|
Research Hours |
300 |
|
|
|
Market Segmentation |
• By Product Type: Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-Cel, Zyntelego, Others • By Therapeutic Class: Rare Diseases, Oncology, Hematology, Cardiovascular, Ophthalmology, Neurology and Other Therapeutic Classes • By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World |
||
|
Regional Segmentation |
• North America – Country Specific Stratification • Europe – Country Specific Stratification • Asia-Pacific – Country Specific Stratification • Latin America – Country Specific Stratification • Rest-of-the-World |
||
|
Growth Drivers |
• Increasing Incidences of Cancer and other Chronic Diseases • Rising Number of Clinical Trials • Increasing Funding and Investments in Cell and Gene Therapy Market • Favorable Regulatory Environment and FDA Approvals for Cell and Gene Therapy Products |
||
|
Market Challenges |
• Lack of Reliable Vector Production for Cell and Gene Therapy • Complex Manufacturing and Distribution Setup • Tedious Process of Therapeutic Commercialization |
||
|
Market Opportunities |
• Drug Approvals and Strong Pipeline of Cell and Gene Therapies • Increasing Number of Mergers and Acquisitions within the Cell and Gene Industry |
||
|
Key Cell and Gene Therapy Companies Profiled |
Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd. |
||
Key Questions Answered in this Report:
• What are the different types of approved cell and gene therapies available in the respective market?
• What are the key development strategies implemented by the key players to stand out in this market?
• What are the various manufacturing considerations within the cell and gene therapy market?
• How have the strategic collaborations among the key players providing a push to product development within the global cell and gene therapy market?
• What are the regulations pertaining to the global cell and gene therapy market in different regions?
• What are the initiatives implemented by different government bodies regulating the development and commercialization of cell and gene therapy products and associated platforms?
• How has COVID-19 impacted the cell and gene therapy market?
• How will the urgency of the pandemic influence the global cell and gene therapy market?
• What are the leading companies dominating the global cell and gene therapy market?
• What is the reimbursement scenario of the products offered in the global cell and gene therapy market?
• Based on the product type, which therapy in the global cell and gene therapy market is anticipated to witness a massive rise in demand in the forecast period?
• How is each segment of the global cell and gene therapy market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2027?
Market Overview
Cell and gene therapy are overlapping fields of biomedical research having similar therapeutic goals, which target DNA or RNA inside or outside the body. Both therapies aim at modifying genetic material for treatment of a disease. Gene therapy uses genetic material, or DNA, to manipulate a patient’s cells for the treatment of an inherited or acquired disease. Cell therapy is the introduction of new cells into a patient’s body to grow, replace or repair damaged tissue to treat a disease. The cell and gene therapies are categorized into several therapeutic class, such as rare diseases, oncology, hematology, cardiovascular, ophthalmology, neurology, and others.
The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is expected to grow at an impressive double-digit rate of 33.82% and reach a value of $25,002.1 million in 2027.
The existing cell and gene therapy market is favored by multiple factors, which include increasing incidences of cancer and other chronic diseases, rising number of clinical trials, increasing funding and investments in the cell and gene therapy market, and favorable regulatory environment and FDA Approvals for cell and gene therapy products.
Within the research report, the market is segmented on the basis of product type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), therapeutic class type (Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Liso-cel, Zyntelego, Others), and region (North America, Europe, Asia Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, and future opportunities, among other analyses, to detail the scope and provide a 360-coverage of the domain.
Competitive Landscape
The global cell and gene therapy market witnessed 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions. 14 mergers and acquisitions, 14 product launches and approvals, 13 joint ventures, and nine business expansions.
Major players within the cell and gene therapy market are Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Dendreon Pharmaceuticals LLC., Human Stem Cells Institute, Kolon TissueGene, Inc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, Shanghai Sunway Biotech Co. Ltd., and Sibiono GeneTech Co. Ltd.
Global Cell and Gene Therapy Market
Focus on Product Type, Therapeutic Class, Pipeline, Regional and Country Data (15 Countries) - Analysis and Forecast, 2021-2027
Some Faq's
Frequently Asked Questions
The cell and gene therapy market is estimated at $2,599.7 million in 2020. The market is expected to grow at a CAGR of 33.82% during the forecast period from 2021 to 2027.
The possible opportunities that can boost the growth of the market include drug approvals and strong pipeline of cell and gene therapies and increasing number of mergers and acquisitions within the cell and gene industry.
Therapeutic class that can be treated with cell and gene therapy include rare diseases, oncology, hematology, cardiovascular, ophthalmology, neurology, and other therapeutic classes.
The factors restraining the growth of the market include lack of reliable vector production for cell and gene therapy, complex manufacturing and distribution setup, and tedious process of therapeutic commercialization.
The key players operating in the market include Amgen Inc., bluebird bio, Inc., Castle Creek Pharmaceutical Holdings., Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., and Spark Therapeutics, Inc.
Similar Product
You may also like
Published Year: 2021
CRISPR Gene Editing Market - A Global and Regional Analysis: Focus on Product, Application, End User
The global CRISPR gene editing market was valued at $1,088.6 million in 2020 and is expected...
Published Year: 2021
Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Dru
The global cell and gene therapy drug delivery devices market was valued at $55.75 thousand in...
Published Year: 2021
Global Cell and Gene Therapy Manufacturing QC Market: Focus on Products and Services, Process, Analy
The global market for cell and gene therapy manufacturing QC is predicted to grow at a CAGR of...